Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

NMRA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$564K, compared with $3.05M a year earlier. Trailing-twelve-month other income / expenses was $745K. Over 3 fiscal years it compounded at -4.3% a year.

Context

  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$564K or moves back toward the trailing-twelve-month quarterly average of $186.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$564K+41.9% QoQ
Last fiscal yearDec 2025
$4.36M-78.1% YoY
LTMMar 2026
$745K-95.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-118.5%——
1 year-78.1%——
3-year CAGR-4.3%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
4.36M USD
Year-over-year change
-78.1%
4-year CAGR
+346.1%

Other Income / Expenses vs competitors

How NMRA compares with its peers on the latest reported figures

  • NMRA's LTM Mar 2026 other income / expenses of $745K is the 7th highest of the 10 companies compared; the peer median is $18.29M.
  • Its year-over-year change of -95.5% is the 8th highest of 10, against a peer median of -30.6%.
  • Over three fiscal years its annual growth of -4.3% compares with a peer median of +113.0%.
NMRA Competitors Peer median
Other Income / Expenses for NMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$191.32M +1815.8%—1933.9%
BCYCBicycle Therapeutics plcLTM Mar 2026$24.78M -37.5%+128.9%39.0%
PRTAProthena Corporation plcLTM Mar 2026$20.28M -10.8%—35.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$18.65M -30.6%+97.1%21.1%
ALMSAlumis Inc. Common StockLTM Jun 2026$18.29M -91.0%+350.3%247.2%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$10.44M -12.7%+54.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$745K -95.5%-4.3%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$1.86M -1250.0%—2.7%
ADCTADC Therapeutics S.A.LTM Mar 2026-$17.66M +27.0%—22.3%
AUTLAutolus Therapeutics plcLTM Mar 2026-$23.51M -111.8%—25.4%
Peer median (excluding NMRA) $18.29M-30.6%+113.0%30.2%

Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00668K05M
Gross Profit00(668K)0(5M)
Gross Margin—————
Research & Development212.78M104.75M142.72M200.93M176.07M
Selling, General & Admin24.55M31.12M44.81M62.54M60.09M
Operating Expenses237.32M135.87M187.53M263.46M236.16M
Depreciation & Amortization538K594K668K631K208K
EBITDA(236.77M)(130.31M)(234.99M)(242.98M)(233.37M)
EBITDA Margin—————
Operating Income(237.32M)(135.87M)(188.19M)(263.46M)(241.16M)
Operating Margin—————
Interest Income04.56M16.61M19.93M8.34M
Interest Expense00003.22M
Other Income / Expenses11K4.97M(47.46M)19.86M4.36M
Income Before Tax(237.31M)(130.9M)(235.66M)(243.61M)(236.8M)
Pre-Tax Margin—————
Income Tax Expense00268K178K130K
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Net Margin—————
EPS (Basic)(1.56)(0.86)(1.49)(1.53)(1.45)
EPS (Diluted)(1.56)(0.86)(1.49)(1.53)(1.45)
Weighted Avg Shares151.95M151.95M158.83M159.38M163.39M
Weighted Avg Shares (Diluted)151.95M151.95M158.83M159.38M163.39M

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.